Senzime AB (publ) (SEZI.ST)
SEK 5.64
(-1.05%)
SEK 5.64
(-1.05%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 141.51 Million SEK | 5.99% |
| 2022 | 133.52 Million SEK | 66.57% |
| 2021 | 80.15 Million SEK | 103.8% |
| 2020 | 39.33 Million SEK | 41.02% |
| 2019 | 27.89 Million SEK | 29.52% |
| 2018 | 21.53 Million SEK | 72.7% |
| 2017 | 12.46 Million SEK | 18.61% |
| 2016 | 10.51 Million SEK | 74.63% |
| 2015 | 6.02 Million SEK | 32.37% |
| 2014 | 4.54 Million SEK | 26.32% |
| 2013 | 3.6 Million SEK | -29.64% |
| 2012 | 5.11 Million SEK | 30.19% |
| 2011 | 3.93 Million SEK | -0.92% |
| 2010 | 3.96 Million SEK | 19.74% |
| 2009 | 3.31 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 37.17 Million SEK | 1.24% |
| 2024 Q2 | 39.41 Million SEK | 6.04% |
| 2023 Q4 | 36.71 Million SEK | 11.8% |
| 2023 FY | 141.51 Million SEK | 5.99% |
| 2023 Q1 | 32.37 Million SEK | -28.39% |
| 2023 Q2 | 37.1 Million SEK | 14.59% |
| 2023 Q3 | 32.84 Million SEK | -11.48% |
| 2022 Q3 | 28.38 Million SEK | -29.11% |
| 2022 Q4 | 45.21 Million SEK | 59.32% |
| 2022 FY | 133.52 Million SEK | 66.57% |
| 2022 Q2 | 40.03 Million SEK | 101.26% |
| 2022 Q1 | 19.89 Million SEK | -17.59% |
| 2021 Q3 | 17.93 Million SEK | -20.57% |
| 2021 Q1 | 15.49 Million SEK | 28.11% |
| 2021 FY | 80.15 Million SEK | 103.8% |
| 2021 Q2 | 22.58 Million SEK | 45.71% |
| 2021 Q4 | 24.13 Million SEK | 34.57% |
| 2020 Q3 | 9.71 Million SEK | -8.76% |
| 2020 Q1 | 7.48 Million SEK | -13.46% |
| 2020 FY | 39.33 Million SEK | 41.02% |
| 2020 Q4 | 12.09 Million SEK | 24.53% |
| 2020 Q2 | 10.64 Million SEK | 42.26% |
| 2019 Q3 | 6.2 Million SEK | -4.1% |
| 2019 FY | 27.89 Million SEK | 29.52% |
| 2019 Q2 | 6.46 Million SEK | -1.15% |
| 2019 Q1 | 6.54 Million SEK | -32.2% |
| 2019 Q4 | 8.64 Million SEK | 39.39% |
| 2018 Q4 | 9.65 Million SEK | 185.56% |
| 2018 FY | 21.53 Million SEK | 72.7% |
| 2018 Q2 | 4.73 Million SEK | 25.51% |
| 2018 Q1 | 3.77 Million SEK | 11.54% |
| 2018 Q3 | 3.38 Million SEK | -28.59% |
| 2017 FY | 12.46 Million SEK | 18.61% |
| 2017 Q4 | 3.38 Million SEK | 45.23% |
| 2017 Q3 | 2.32 Million SEK | -22.96% |
| 2017 Q2 | 3.02 Million SEK | -21.38% |
| 2017 Q1 | 3.84 Million SEK | 6.48% |
| 2016 Q4 | 3.61 Million SEK | 31.46% |
| 2016 FY | 10.51 Million SEK | 74.63% |
| 2016 Q3 | 2.74 Million SEK | 13.89% |
| 2016 Q2 | 2.41 Million SEK | 38.12% |
| 2016 Q1 | 1.74 Million SEK | 0.11% |
| 2015 Q3 | 1.49 Million SEK | -8.49% |
| 2015 Q4 | 1.74 Million SEK | 16.62% |
| 2015 Q1 | 1.14 Million SEK | -23.4% |
| 2015 FY | 6.02 Million SEK | 32.37% |
| 2015 Q2 | 1.63 Million SEK | 42.33% |
| 2014 Q1 | 963.99 Thousand SEK | 24.09% |
| 2014 FY | 4.54 Million SEK | 26.32% |
| 2014 Q2 | 1.27 Million SEK | 32.1% |
| 2014 Q3 | 822.67 Thousand SEK | -35.4% |
| 2014 Q4 | 1.49 Million SEK | 82.14% |
| 2013 FY | 3.6 Million SEK | -29.64% |
| 2013 Q3 | 679.82 Thousand SEK | -36.58% |
| 2013 Q1 | 1.07 Million SEK | 107.99% |
| 2013 Q4 | 776.81 Thousand SEK | 14.27% |
| 2013 Q2 | 1.07 Million SEK | -0.0% |
| 2012 FY | 5.11 Million SEK | 30.19% |
| 2012 Q4 | 515.37 Thousand SEK | 0.0% |
| 2011 FY | 3.93 Million SEK | -0.92% |
| 2010 FY | 3.96 Million SEK | 19.74% |
| 2009 FY | 3.31 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | -70.811% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 76.869% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 76.869% |
| Arcoma AB | 53.25 Million SEK | -165.75% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -2747.998% |
| BICO Group AB (publ) | 2.84 Billion SEK | 95.032% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 32.753% |
| CellaVision AB (publ) | 295.99 Million SEK | 52.189% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -105.305% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -10709.566% |
| C-Rad AB (publ) | 3.8 Million SEK | -3624.132% |
| Duearity AB (publ) | 21.58 Million SEK | -555.627% |
| Dignitana AB (publ) | 74.73 Million SEK | -89.356% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -5141.37% |
| Getinge AB (publ) | 10.75 Billion SEK | 98.685% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -676.348% |
| Iconovo AB (publ) | 63.35 Million SEK | -123.374% |
| Integrum AB (publ) | 90.57 Million SEK | -56.249% |
| Luxbright AB (publ) | 23.09 Million SEK | -512.879% |
| Mentice AB (publ) | 237.06 Million SEK | 40.303% |
| OssDsign AB (publ) | 175.6 Million SEK | 19.41% |
| Paxman AB (publ) | 133.8 Million SEK | -5.768% |
| Promimic AB (publ) | 48.55 Million SEK | -191.475% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 12.851% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -102.236% |
| ScandiDos AB (publ) | 61.03 Million SEK | -131.851% |
| Sectra AB (publ) | 39.06 Million SEK | -262.279% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 18.914% |
| SpectraCure AB (publ) | 12.12 Million SEK | -1066.862% |
| Stille AB | 87.21 Million SEK | -62.255% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 97.458% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 67.904% |